Treatment of pemphigus
AssigneesBiogen, Inc., Genentech, Inc.
InventorsJohn G. Curd, Antonio J. Grillo-Lopez
Life of this patent
Estimating the term…
Abstract
The present invention concerns treatment of pemphigus with an antibody which binds to CD20.
Claims18
A method of treating an autoimmune disease in a human comprising administering to the human a therapeutically effective amount of an antibody that binds human CD20 and depletes human B-cells, wherein the autoimmune disease consists of pemphigus.
A method of treating an autoimmune disease in a human comprising administering to the human a therapeutically effective amount of rituximab, wherein the autoimmune disease consists of pemphigus.
A method of treating pemphigus in a human comprising administering to the human a therapeutically effective amount of rituximab and further comprising administering to the human other compounds comprising steroid and mycophenolic acid, wherein the other compounds are coadministered or consecutively administered in either order with the rituximab.
A method of treating pemphigus in a human who does not have an autoimmune disease other than pemphigus comprising administering to the human a therapeutically effective amount of an antibody that binds human CD20 and depletes human B-cells.
A method of treating pemphigus in a human who does not have an autoimmune disease other than pemphigus comprising administering to the human a therapeutically effective amount of rituximab.
A method of treating pemphigus in a human who does not have an autoimmune disease other than pemphigus comprising administering to the human a therapeutically effective amount of rituximab and further comprising administering to the human other compounds comprising steroid and mycophenolic acid, wherein the other compounds are coadministered or consecutively administered in either order with the rituximab.
Dependencies are inferred from the claim text.